首页 / 院系成果 / 成果详情页

Delivery of epirubicin via slow infusion as a strategy to mitigate chemotherapy-induced cardiotoxicity 期刊论文

编号：

9b77ea58-3075-4223-b018-571acf23cab6
作者：

Yang, Fang#^[1,2]Lei, Qiao#^[1,2]Li, Lu^[3];He, Jian Chang^[4];Zeng, Jiajia^[1,2];Luo, Chunxiang^[1,2];Yeung, SaiChing Jim^[5,6];Yang, Runxiang(杨润祥)*^[1,2]
语种：

英文
期刊：

PLOS ONE ISSN：1932-6203 2017 年 12 卷 11 期 ; NOV 13
收录：
摘要：

Background
Continuous infusion of doxorubicin has been a strategy to reduce cardiotoxicity. Epirubicin is another anthracycline in common clinical use. However, evidence is lacking regarding whether this strategy can reduce cardiotoxicity of epirubicin without compromising antineoplastic efficacy.
Design and methods
Healthy rats were randomized into groups: epirubicin (8 mg/kg) delivered intraperitoneally via micro osmotic pumps (MOP), epirubicin (8 mg/kg) by intraperitoneal (IP) bolus injection, and placebo control. Blood samples were collected for analyzing biomarkers of myocardial injury and pharmacokinetics. At chosen times, sub-groups of animals were sacrificed for histopathology. A mouse breast cancer cell line (4T1), stably transfected with luciferase, was orthotopically allografted in female mice, and treated in three groups as described above for the rats. Tumor growth was monitored by measuring tumor size as well as bioluminescence.
Results
Delivery by IP bolus and by MOP achieved essentially the same area under the curve of epirubicin plasma concentration time profile. Blood biomarkers showed that the degree of myocardial injury in MOP group was lower than that of IP group. Histopathology showed that there was less eosinophilic enhancement, interstitial hemorrhage and necrotizing muscle atrophy in MOP group than IP group. In the orthotopic breast cancer allograft mouse model, the antineoplastic effect of epirubicin by MOP was not different from that by IP as measured by tumor weights or by in vivo bioluminescence.
Conclusion
Slow delivery of epirubicin by MOP reduced cardiotoxicity without compromising the antineoplastic effect compared to IP bolus delivery. These in vivo data support our previous clinical data that continuous intravenous infusion of epirubicin using micro infusion pumps over 48-96 hours had less cardiotoxicity than intravenous bolus injections. However, whether multiple doses of epirubicin given by MOP result in a lower magnitude of long term cardiomyopathy remains to be further investigated.
推荐引用方式
GB/T 7714：

Yang Fang,Lei Qiao,Li Lu, et al. Delivery of epirubicin via slow infusion as a strategy to mitigate chemotherapy-induced cardiotoxicity [J].PLOS ONE,2017,12(11).
APA：

Yang Fang,Lei Qiao,Li Lu,He Jian Chang,&Yang Runxiang.(2017).Delivery of epirubicin via slow infusion as a strategy to mitigate chemotherapy-induced cardiotoxicity .PLOS ONE,12(11).
MLA：

Yang Fang, et al. "Delivery of epirubicin via slow infusion as a strategy to mitigate chemotherapy-induced cardiotoxicity" .PLOS ONE 12,11(2017).
条目包含文件：

文件类型：PDF,文件大小：

正在加载全文

未找到全文

浏览次数：76  下载次数：0

分享到：

浏览次数：76

下载次数：0

打印次数：0